Reply To: Vyvgart to treat CIDP

January 3, 2024 at 3:58 pm

Hello Chrpybirdy,
<div>I have CIDP as well and understand your dilemma. Argenx has ongoing studies for use of efgartigimod alfa (Vyvgart)for use in CIDP. They also have a version with hyaluronidase. It antagonizes the neonatal Fc receptor reducing circulating Ig including autoantibodies). The thought is it will reduce or eliminate the bad Ig that attacks your nerve junctions that causes the untoward effects caused by CIDP. The hope is it will be equally as effective as Ig (IV or SubQ) or better. You are correct that Vyvgart is currently only approved in the US for Myasthenia Gravis (MG). You might want to contact Argenx USA to gather more information.  I believe many of us are awaiting to see what results the phase two trials show and see it move into phase three. You can also reach out to one of the physician specialists at a center of excellence listed on the GBS-CIDP Foundation web-site and email them a question regarding this novel agent.  Good luck on your journey and hopefully this is helpful.</div>
<div>Dave Tuck, PharmD</div>